Relative to expanding the definition of providers who can certify patients of the therapeutic cannabis program.
Impact
The bill is poised to have a considerable impact on state laws regarding the prescribing of therapeutic cannabis. By including additional licensed providers, it is anticipated that more patients will be able to receive essential care without the need for a narrow scope of certification. This could potentially lead to an increase in the number of registered patients within the therapeutic cannabis program, thus changing the landscape of patient support and care options in New Hampshire.
Summary
Senate Bill 357 aims to expand the definition of providers eligible to certify patients under New Hampshire's therapeutic cannabis program. This amendment allows various healthcare providers, including those licensed in neighboring states like Maine, Massachusetts, and Vermont, and those with DEA registration to prescribe controlled substances, to legally offer certifications for cannabis patients. This is significant as it broadens access to therapeutic cannabis for individuals with qualifying medical conditions, thereby enhancing available treatment options.
Contention
Notable points of contention surrounding SB 357 may involve discussions about the implications of allowing non-physicians to certify patients, as critics might express concerns regarding prescribing practices and medical oversight. Additionally, the requirement for minors to have certifications from two providers, including a pediatric provider, exemplifies a cautious approach to safeguard vulnerable populations. Some stakeholders may argue about the adequacy of oversight in this expanded model and whether it sufficiently protects patient health while providing necessary access.
Expanding the definition of providers who can certify patients of the therapeutic cannabis program and relative to release of a defendant pending trial and relative to product labeling and information guide requirements for cannabis products and the prohibition of the sale of hemp products containing certain levels of THC.
Relative to eligibility criteria for the therapeutic cannabis program and establishing a commission to study state-controlled sales of cannabis and relative to the prohibition on the sale of hemp products containing certain levels of THC.